Combination therapy for cancer treatment

ABSTRACT

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.

TECHNICAL FIELD

This invention relates to the treatment of cancer with aPoly(ADP-ribose) polymerase (PARP) inhibitor and a topoisomeraseinhibitor.

BACKGROUND

Liposomal irinotecan and PARP inhibitors are therapies useful in thetreatment of cancer. Liposome encapsulated irinotecan formulations ofthe topoisomerase inhibitor irinotecan provide sustained exposure ofirinotecan and the metabolite SN-38 in a tumor. ONIVYDE (irinotecanliposome injection) is an example of liposomal irinotecan recentlyapproved in the United States for the treatment of patients withmetastatic adenocarcinoma of the pancreas after disease progressionfollowing gemcitabine-based therapy. Poly(ADP-ribose) polymerases are afamily of enzymes involved in DNA repair believed to act via twomechanisms: catalytic inhibition and trapping of PARP-DNA complexes, andinhibition of this repair pathway can result in cell death following DNAdamage. PARP inhibitors are a new class of chemotherapeutic agentscurrently in development for the treatment of various cancer types.

While certain combinations of PARP and topoisomerase inhibitors haveshown to be synergistic in in vitro assays, the clinical development ofPARP inhibitor and topoisomerase inhibitor combinations has been limiteddue to increased toxicities and resultant dose reductions, therebylimiting the potential clinical utility of the combination. For example,significant myelosuppression was seen in a dose-escalation study ofveliparib and topotecan, wherein the maximum tolerated dose was exceededat the first planned dose level. Most PARP inhibitors are beingdeveloped to date solely as monotherapies. As a result, there is a needfor methods to safely and effectively combine a PARP inhibitor with aTop1 inhibitor to treat cancer.

SUMMARY

The present disclosure provides methods of treating cancer byadministering a topoisomerase inhibitor and a PARP inhibitor withreduced peripheral toxicity. This can be accomplished by administeringthe topoisomerase inhibitor in a form (e.g., liposomal irinotecan) thatprolongs accumulation of the topoisomerase inhibitor in a tumor relativeto sites outside the tumor, and then subsequently administering the PARPinhibitor(s) to the patient after an interval between the administrationof the topoisomerase inhibitor and the PARP inhibitor. The interval canbe selected to provide enough time for the topoisomerase inhibitor(e.g., irinotecan and/or its metabolite SN-38) to clear plasma or tissueoutside of the tumor to a greater extent than inside the tumor.Preferably, the interval is an effective topoisomerase-1 inhibitorplasma clearing interval. As used herein, the term “effectivetopoisomerase-1 inhibitor plasma clearing interval” (e.g., irinotecanplasma clearing interval) is that interval between concluding theadministration of a topoisomerase-1 inhibitor formulation (e.g.,liposomal irinotecan) and initiating the administration of one or morePARP inhibitors, where the time interval is selected to allow sufficientclearance of the topoisomerase-1 inhibitor (e.g., irinotecan or itsactive metabolite SN-38) from the blood plasma (or peripheral tissue)but allows an effective quantity of the topoisomerase-1 inhibitor (e.g.,irinotecan and/or SN38) to remain in one or more tumors within thepatient during the subsequent administration of the PARP inhibitor in anamount effective to provide a desired effect on the tumor (e.g.,heightened combined toxicity localized within the tumor). Preferably,she PARP inhibitor is administered after an irinotecan plasma clearinginterval of 3-5 days (e.g., 3, 4 or 5 days) after completing theadministration of liposomal irinotecan on days 1 and 15 during each ofone or more 28-day treatment cycles.

Methods of treating cancer disclosed herein include the treatment ofsolid tumors. In certain examples, the cancer treated can be selectedfrom the group consisting of cervical cancer, ovarian cancer, triplenegative breast cancer, non-small cell lung cancer, small cell lungcancer, gastrointestinal stromal tumors gastric cancer, pancreaticcancer, colorectal cancer, and a neuroendocrine cancer. Preferably, thecancer is cervical cancer.

The topoisomerase inhibitor can be provided as a liposome formulation.Preferably, the topoisomerase inhibitor is a liposomal irinotecan. Theliposomal irinotecan can provide an irinotecan terminal eliminationhalf-life of 26.8 hours and a maximal irinotecan plasma concentration of38.0 micrograms/ml. In some examples, the liposomal irinotecan caninclude irinotecan sucrose octasulfate encapsulated within phospholipidvesicles having a size of about 110 nm. For example, the liposomalirinotecan can be the product ONIVYDE® (irinotecan liposome injection)(Merrimack Pharmaceuticals, Inc. Cambridge, Mass.), previouslydesignated “MM-398.” The PARP inhibitor can include one or morecompounds selected from the group consisting of niraparib, olaparib,veliparib, and rucaparib, preferably veliparib or olaparib.

The topoisomerase-1 inhibitor is preferably a liposomal irinotecan(e.g., MM-398), which can be administered at dose of 80 mg/m² (salt)irinotecan once every 2 weeks in combination with a PARP inhibitor(e.g., veliparib, olaparib. niraparib or rucaparib) administered dailyduring each two week cycle starting 3-5 days after administration ofliposomal irinotecan without administering the PARP inhibitor on dayswhen the liposomal irinotecan is administered (e.g., withoutadministering the PARP inhibitor 1, 2 or 3 days before the nextliposomal irinotecan administration). Preferably, the PARP inhibitor isnot administered within 3 days of (i.e., neither 3 days after nor 3 daysbefore) the administration of liposomal irinotecan.

Specific methods of treating a cancer provided herein includeadministering an antineoplastic therapy consisting of the administrationof liposomal irinotecan every 2 weeks (e.g., on days 1 and 15 of a28-day treatment cycle), and the administration of a PARP inhibitor oneor more times per day (e.g., twice per day) for one or more days (e.g.,7-9 days) starting at least 3 days (e.g., 3, 4 or 5 days) after eachadministration of the liposomal irinotecan, without administering otherantineoplastic agents during the antineoplastic therapy. For example,one antineoplastic therapy is a 28-day treatment cycle consisting of:administering 70 mg/m² MM-398 liposomal irinotecan (free base) on days 1and 15, and administering a therapeutically effective amount of the PARPinhibitor (e.g., 50-400 mg twice per day for veliparib) on each of days5-12 and days 19-25 of the treatment cycle, where no otherantineoplastic agent is administered during the treatment cycle. Anotherantineoplastic therapy is a 28-day treatment cycle consisting of:administering 70 mg/m² MM-398 liposomal irinotecan (free base) on days 1and 15, and administering a therapeutically effective amount of the PARPinhibitor (e.g., 50-400 mg twice per day for veliparib) on each of days3-12 and days 17-25 of the treatment cycle, where no otherantineoplastic agent is administered during the treatment cycle.

In some examples, liposomal irinotecan and a PARP inhibitor can becombined in an antineoplastic therapy for the treatment of a solidtumor, comprising a 28-day antineoplastic therapy treatment cycleconsisting of: administering the liposomal irinotecan on days 1 and 15of the treatment cycle, and administering the PARP inhibitor on one ormore days starting at least 3 days after the liposomal irinotecan andending at least 1 day prior to administration of additional liposomalirinotecan. In some examples, the PARP inhibitor is not administered forat least 3 days after the administration of liposomal irinotecan. Forexample, the PARP inhibitor can be administered on one or more of days5-12 of she antineoplastic therapy treatment cycle, and administered onone or more of days 19-25 of the antineoplastic therapy treatment cycle.In some examples, the PARP inhibitor is administered on one or more ofdays 3-12 of the antineoplastic therapy treatment cycle, andadministered on one or more of days 17-25 of the antineoplastic therapytreatment cycle. In some examples, the PARP inhibitor is notadministered within 3 days before or after the administration of theliposomal irinotecan.

In addition, therapeutically effective doses of the topoisomeraseinhibitor and PARP inhibitor compounds are provided herein. In someexamples, each administration of liposomal irinotecan is administered ata dose of 80 mg/m² (salt) of MM-398. In some examples, eachadministration of the PARP inhibitor is administered at a dose of fromabout 20 mg/day to about 800 mg/day. Each administration of the PARPinhibitor can be administered once or twice daily at a dose of fromabout 20 mg/day to about 400 mg/day.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a graph showing the results of a cell viability in vitromeasurement of ME-180 human cervical cancer cells treated with thetopoisomerase 1 inhibitor SN-38 and various PARP inhibitors.

FIG. 1B is a graph showing the results of a cell viability in vitromeasurement of MS-751 human cervical cancer cells treated with thetopoisomerase 1 inhibitor SN-38 and various PARP inhibitors.

FIG. 1C is a graph showing the results of a cell viability in vitromeasurement of C-33A human cervical cancer cells treated with thetopoisomerase 1 inhibitor SN-38 and various PARP inhibitors.

FIG. 1D is a graph showing the results of a cell viability in vitromeasurement of SW756 human cervical cancer cells treated with thetopoisomerase 1 inhibitor SN-38 and various PARP inhibitors.

FIG. 1E is a graph showing the results of a cell viability in vitromeasurement of SiHa human cervical cancer cells treated with thetopoisomerase 1 inhibitor SN-38 and various PARP inhibitors.

FIG. 2A is a graph showing the results of in vitro measurement of % cellnumber over time for DMS-114 small cell lung cancer cells treated withthe topoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib.

FIG. 2B is a graph showing the results of in vitro measurement of % cellnumber over time for NCI-H1048 small cell lung cancer cells treated withthe topoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib.

FIG. 2C is a graph showing the results of in vitro measurement of % cellnumber over time for CFPAC-1 pancreatic cancer cells treated with thetopoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib.

FIG. 2D is a graph showing the results of in vitro measurement of % cellnumber over time for BxPC-3 pancreatic cancer cells treated with thetopoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib.

FIG. 2E is a graph showing the results of in vitro measurement of % cellnumber over time for MDA-MB-231 triple negative breast cancer (TNBC)cancer cells treated with the topoisomerase inhibitor SN-38 and the PARPinhibitor rucaparib.

FIG. 3A is a graph showing the results of in vitro measurement of cellsurvival for BT-20 triple negative breast cancer (TNBC) cancer cellstreated with the topoisomerase inhibitor SN-38 and the PARP inhibitortalazoparib.

FIG. 3B is a graph showing the results of in vitro measurement of cellsurvival for HCC38 triple negative breast cancer (TNBC) cancer cellstreated with the topoisomerase inhibitor SN-38 and the PARP inhibitortalazoparib.

FIG. 4 depicts a graphical representation of a murine tolerability studydesign comparing MM-398 and olaparib as a monotherapy or in combinationusing a fixed dose of MM-398 and varying doses of olaparib, with variousdosing schedules for different groups.

FIG. 5A is a graph showing the results of a murine tolerability study ofa combination of MM-398 and veliparib, measuring % change in bodyweightafter administration of 15 mg/kg of MM-398 on day 1, and 50 mg/kg ofveliparib on days 2, 3, and 4.

FIG. 5B is a graph showing the results of a murine tolerability study ofa combination of MM-398 and veliparib, measuring % change in bodyweightafter administration of 28 mg/kg of MM-398 on day 1, and 50 mg/kg ofveliparib on days 3, 4, and 5.

FIG. 5C is a graph showing the results of a murine tolerability study ofa combination of MM-398 and veliparib, measuring % change in bodyweightafter administration of 50 mg/kg of MM-398 on day 1, and 50 mg/kg ofveliparib on days 4, 5, and 6.

FIG. 6A is a graph comparing the results of a murine tolerability studymeasuring % change in bodyweight after administration of 10 mg/kg ofMM-398 (+PBS); 200 mg/kg/day of Olaparib; 10 mg/kg of MM-398 (+PBS) with200 mg/kg/day of Olaparib on days 1-4; and 10 mg/kg of MM-398 (+PBS)with 200 mg/kg/day of Olaparib on days 1-5.

FIG. 6B is a graph comparing the results of a murine tolerability studymeasuring % change in bodyweight after administration of 10 mg/kg ofMM-398 (+PBS) and 200 mg/kg/day of Olaparib.

FIG. 6C is a graph comparing the results of a murine tolerability studymeasuring % change in bodyweight after administration of 10 mg/kg ofMM-398 (+PBS); 10 mg/kg of MM-398 (+PBS) with 200 mg/kg/day of Olaparibon days 1-4; and 10 mg/kg of MM-398 (+PBS) with 200 mg/kg/day ofOlaparib on days 1-5.

FIG. 6D is a graph comparing the results of a murine tolerability studymeasuring % change in bodyweight after administration of 10 mg/kg ofMM-398 (+PBS); 10 mg/kg of MM-398 (+PBS) with 200 mg/kg/day of Olaparibon days 1-5; 10 mg/kg of MM-398 (+PBS) with 150 mg/kg/day of Olaparib ondays 1-5; and 10 mg/kg of MM-398 (+PBS) with 265 mg/kg/day of Olaparibon days 3-5.

FIG. 7A is a graph showing data from a mouse xenograft study using MS751cervical cancer cells in a murine model treated with liposomalirinotecan (5 mg/kg MM398) and/or the PARP inhibitor veliparib on days4-6 after administration of MM398.

FIG. 7B is a graph showing data from a mouse xenograft study using MS751cervical cancer cells in a murine model treated with liposomalirinotecan (2 mg/kg MM398) and/or the PARP inhibitor veliparib on days4-6 after administration of MM398.

FIG. 8A is a graph that depicts the in vivo tolerability of 50 mg/kgdose of MM-398 in combination with 50 mg/kg veliparib given on days 1,2, and 3; or 2, 3, and 4; or 3, 4, and 5 after administration of theMM-398.

FIG. 8B is a graph that depicts the in vivo tolerability of 28 mg/kgdose of MM-398 in combination with 50 mg/kg veliparib given on days 1,2, and 3; or 2, 3, and 4; or 3, 4, and 5 after administration of theMM-398.

FIG. 9A is a graph showing data from a mouse xenograft study using MS751cervical cancer cells in a murine model treated with liposomalirinotecan (5 mg/kg MM398) and/or the PARP inhibitor veliparib (50 mpk)on days 3-5 starting after administration of MM398.

FIG. 9B is a graph showing survival data from a mouse xenograft studyusing MS751 cervical cancer cells in a murine model treated withliposomal irinotecan (5 mg/kg MM398) and/or the PARP inhibitor veliparib(50 mpk) on days 3-5 starting after administration of MM398.

FIG. 9C is a graph that depicts the effect of MM-398 in combinationswith veliparib in MS751 xenograft murine model treated with liposomalirinotecan (5 mg/kg MM398) and/or the PARP inhibitor veliparib (50 mpk)on days 3-5 starting after administration of MM398.

FIG. 10 is a graph showing data from a mouse xenograft study using C33cervical cancer cells in a murine model treated with liposomalirinotecan (2 mg/kg MM398) and/or the PARP inhibitor veliparib (50 mpk)on days 3-5 starting after administration of MM398.

FIG. 11 is a graph showing survival data from a mouse xenograft studyusing C33 cervical cancer cells in a murine model treated with liposomalirinotecan (5 mg/kg MM398) and/or the PARP inhibitor veliparib (50 mpk)on days 3-5 starting after administration of MM398.

FIG. 12 depicts the effect of MM-398 in combination with veliparib inC33A xenograft model and body weight, where veliparib was dosed 72 hfollowing liposomal irinotecan (5 mg/kg MM398) and/or the PARP inhibitorveliparib (50 mpk) on days 3-5 starting after administration of MM398.

FIG. 13A is a graph showing the in vitro activity (IC50) for multiplecervical cancer cell lines treated with veliparib and SN38, addedtogether or with the veliparib added 24 hours after the SN38.

FIG. 13B is a graph showing the cell viability (CTG assay) in nude micewith cervical cancer tumors, injected with a single dose of MM-398 (10mg/kg) followed by measurement of irinotecan and SN38 content in thetumor measured by LC-MS.

FIG. 14 is a graphical representation of a phase I study designemploying the combinations of MM-398 (nal-IRI) and veliparib.

FIG. 15A is a schematic showing a use of ferumoxytol (FMX) as apredictive biomarker for cancer treatment with liposomal irinotecan(e.g., MM-398).

FIG. 15B is a graph showing FMX concentration of individual patientlesions was calculated using a standard curve from MR images obtained 24h post-FMX injection.

FIG. 15C is a graph showing FMX signal from lesions at 24 h are groupedrelative to the median value observed in the FMX MRI evaluable lesionsand compared to the best change in lesion size based on CT scans (dataavailable from 9 patients; total of 31 lesions).

FIG. 16A is a graph showing the tumor SN-38 (nmol/L) measured in tumorsafter administration of free (non-liposomal) irinotecan (CPT-11) at 50mg/kg or 100 mg/kg, compared to the administration of MM-398 (5 mg/kg,10 mg/kg or 20 mg/kg).

FIG. 16B is a graph showing levels of tumor growth inhibition as afunction of time of SN-38 concentration required to yield tumorresponse.

DETAILED DESCRIPTION

The present disclosure provides for methods of administering acombination of a topoisomerase-1 (Top1) inhibitor (e.g., irinotecanand/or its metabolite SN-38) and a PARP inhibitor to a tumor withreduced peripheral toxicity. The Top1 inhibitor can be administered in aliposome formulation resulting in the prolonged accumulation of the Top1inhibitor in a solid tumor compared to peripheral plasma and/or healthyorgans. Subsequently, a PARP inhibitor can be administered after aperiod of time permitting a reduction in the amount of the Top1inhibitor outside the tumor relative to the amount of Top1 inhibitorwithin the tumor. Preferably, the Top1 inhibitor is administered as aliposomal irinotecan that provides SN-38 to a solid tumor.

Methods of treating a cancer are provided, as well as therapeutic usesof PARP inhibitor compounds in combination with liposomal irinotecanformulations for the treatment of cancer, particularly cancer comprisingsolid tumors. These uses and methods can provide a treatment regimencomprising: (a) administering to a patient in need thereof an effectiveamount of an irinotecan liposomal formulation; and (b) after completionof the administration of the Top1 inhibitor, administering to thepatient an effective amount of a PARP inhibitor, wherein the PARPinhibitor is administered to the patient following an interval thatallows for a reduction in peripheral toxicity as compared tosimultaneous administration of the Top1 inhibitor and the PARPinhibitor. The interval can be selected to provide time for sufficientclearance of the Top1 inhibitor (e.g., either or both of irinotecan andSN-38) from the blood plasma to avoid peripheral toxicity due to thesynergistic toxic effects of the combination of Top1 inhibitor and PARPinhibitor, while allowing an effective quantity of Top1 inhibitor toremain in one or more tumors within the patient for the subsequentadministration of the PARP inhibitor to have a desired synergistictherapeutic effect. This treatment regimen can preferably provide one ormore attributes, which may include increased efficacy of the combinationas compared to single agent treatment; reduced side effects, dosing thedrugs at a higher dose compared with administration of the combinationof a PARP inhibitor and a non-liposomal Top1 inhibitor.

The uses and methods disclosed herein are based in part on experimentsevaluating the combination of a topoisomerase 1 inhibitor (e.g.,liposomal irinotecan or SN-38) and a PARP inhibitor in both pre-clinicaland human clinical studies. The topoisomerase 1 inhibitor wasadministered in certain in vitro animal models using a formulationdelivering a more prolonged exposure of the topoisomerase 1 inhibitor(e.g., irinotecan and/or the irinotecan active metabolite designatedSN-38) within solid tumors than in peripheral tissue and plasma outsidethe tumor. Combinations of the topopisomerase 1 inhibitor SN38 and/oririnotecan and PARP inhibitor compounds were rested in various in vitroexperiments. As detailed in Example 1, the in vitro testing of multiplecombinations of a topoisomerase 1 inhibitor (SN38) and various PARPinhibitors in more than 20 different cancer cell lines (includingcervical, breast, ovarian, colorectal, pancreatic, and small cell lungcancer cell lines) all demonstrated decreased cancer cell line viability(FIGS. 1A, 1B, 1C, 1D, 1E, 2A, 2B, 2C, 2D, 2E, and 13A). The liposomalirinotecan (MM398) demonstrated greater tumor volume reduction thannon-liposomal (free) irinotecan (CPT11) in mouse xenograft studiesacross multiple types of cancer cell lines (including breast, ovarian,colorectal and pancreatic cancer cell lines).

As detailed in Example 2, the tolerability of a topoisomerase 1inhibitor (liposomal irinotecan) administered in combination withvarious PARP inhibitors was evaluated by measuring the change in animal(mouse) body weight in multiple murine models by comparing variousdosing schedules. In some experiments, both liposomal irinotecan and aPARP inhibitor were administered together on the same day (day 1). Inother experiments, the PARP inhibitor was first administered dailystarting 2, 3 or 4 days after each administration of the liposomalirinotecan. The PARP inhibitor was administered for multiple consecutivedays (e.g., 3 consecutive days), and not administered on the same day asthe topoisomerase 1 inhibitor. As detailed in multiple experimentsherein, administration oi the PARP inhibitor at least one day after theliposomal irinotecan resulted in improved tolerability of comparablecombined doses of the PARP inhibitor and liposomal irinotecan (MM-398)as measured by change in percent bodyweight in the animal (e.g., FIGS.6A, 6B, 6C, 6D, 8A, and 8B). Delaying the administration of the PARPinhibitor 2, 3 or 4 days after administration of the liposomalirinotecan led to greater overall tolerability of a combinedadministration of the liposomal irinotecan and the PARP inhibitor,compared to the administration of the liposomal irinotecan and the PARPinhibitor on the same day. For example, administration of veliparib ondays 2, 3 and 4 after administration of liposomal irinotecan on day 1resulted in successively increased tolerability (measured as higherpercent mouse bodyweight) of the combination of these two drugs(observed at 15 mg/kg liposomal irinotecan dose an day 1 followed byveliparib dosing on days 2, 3 and 4 (FIG. 5A); at 28 mg/kg liposomalirinotecan dosage on day 1 followed by veliparib dosing on days 3, 4,and 5 (FIGS. 5B and 8B), or followed by veliparib dosing on days 2, 3and 4 (FIG. 8B); and at 50 mg/kg liposomal irinotecan dose on day 1followed by veliparib dosing on days 4, 5 and 6 (FIG. 5C), or followedby veliparib dosing on days 2, 3 and 4 or followed by veliparib dosingon days 3, 4, and 5 (FIG. 8A)). Similarly, administering olaparibstarting on days 2 or 3 after MM398 resulted in comparable or improvedtolerability compared to administration of both agents on day 1. Forexample, administering a 200 mg/kg dose of olaparib to mice on days 2,3, 4 and 5 after administration of 10 mg/kg MM398 liposomal irinotecanon day 1 resulted in a lower reduction in bodyweight than administeringthe same doses of both MM398 and olaparib on days 1, 2, 3 and 4.

Combinations of a topoisomerase 1 inhibitor (SN38 and/or irinotecan) andPARP inhibitor compounds were tested in various preclinical in vivoexperiments to evaluate the effectiveness of the administration ofvarious PARP inhibitors starting 3 or 4 days after administration of theliposomal topoisomerase 1 inhibitor MM398. As detailed in Example 3, theadministration of liposomal irinotecan (MM398) on day 1 followed by thePARP inhibitor veliparib on either days 3, 4 and 5 or days 4, 5, and 6,resulted in decreased tumor volume and extended percent survival inmouse xenograft models of cervical cancer using two different cell lines(MS751 and C33A) (FIGS. 7A, 7B, 9A, 9B, 10 and 11).

Based in part on these experiments, methods of treating human cancerinclude the administration of a PARP inhibitor one or more days(preferably 2, 3, 4, 5 or 6 days) after the administration of liposomaltopoisomerase inhibitor such as liposomal irinotecan. Preferably, thePARP inhibitor and the liposomal irinotecan are not administered on thesame day. Example 3 provides preferred embodiments for the use ofliposomal irinotecan and one or more PARP inhibitors for the treatmentof human cancer, such as cervical cancer, while other embodiments (e.g.,Table 3) are also provided.

Topoisomerase Inhibitors, Including Liposomal Irinotecan andCamptothecin Conjugates

The topoisomerase inhibitor can be administered in any form thatprovides for the prolonged retention of a topoisomerase-1 inhibitoractivity within a tumor compared to outside the tumor, afteradministration of the topoisomerase inhibitor. For example, thetopoisomerase inhibitor can be a formulation that delivers SN-38 to atumor cell in vivo, administered in an amount and manner providing ahigher concentration of the SN-38 within the tumor than outside thetumor for a period of time after administration of the topoisomeraseinhibitor. Suitable formulations of topoisomerase inhibitors includeconjugate molecules of a topoisomerase inhibitor (e.g., camptothecinconjugated to a polymer or antibody), liposomes containing atopoisomerase inhibitor or other targeted release formulationtechnologies. The Top1 inhibitor is preferably formulated to provideprolonged accumulation in a tumor site, compared to accumulation inhealthy (non-cancer) tissue outside the tumor site (e.g., in the plasmaand/or healthy organs such as colon, duodenum, kidney, liver, lung andspleen). Various Top1 inhibitor liposomal formulations are described inU.S. Pat. No. 8,147,867 and U.S. Patent Application Publication No.2015/0005354, both of which are incorporated herein by reference.

In one embodiment, the topoisomerase inhibitor is SN-38, camptothecin ora compound that is converted to SN-38 within the body, such asirinotecan. Irinotecan and SN-38 are examples of Top1 inhibitors.Irinotecan is converted by esterase enzymes into the more activemetabolite, SN-38. The chemical name of irinotecan is(S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[4′,4′:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4′bipiperidine]-1′-carboxylate.Irinotecan hydrochloride trihydrate is also referred to by the nameCPT-11 and by the trade name CAMPTOSAR®.

The topoisomerase inhibitor can be camptothecin conjugated to abiocompatible polymer such as a cyclodextrin or cyclodextrin analog(e.g., sulfonated cyclodextrins). For example, the topoisomeraseinhibitor can be a cyclodextrin-containing polymer chemically bound to acamptothecin, irinotecan, SN-38 or other topoisomerase 1 inhibitorcompound. A cyclodextrin-camptothecin conjugated topoisomerase 1inhibitor can be administered at a pharmaceutically acceptable doseincluding 6, 12, or 18 mg/m2 weekly administration, or 12, 15 or 18mg/m2 biweekly administration. Examples of camptothecin-cyclodextrinconjugate topoisomerase 1 inhibitors (e.g., the cyclodextrin-containingpolymer conjugate with camptothecin designated “CRLX101”), and relatedintermediates for preparing the same, are disclosed, for example, inGreenwald et al., Bioorg. Med. Chem., 1998, 6, 551-562, as well asUnited States Patent Application 2010/0247668, United States PatentApplication 2011/0160159 and United States Patent Application2011/0189092.

The topoisomerase inhibitor can also be a liposomal formulation of atopoisomerase inhibitor such as irinotecan, camptothecin or topotecan.Liposomal irinotecan (e.g., MM-398, also called “nal-IRI”) is a highlystabilized liposomal formulation of irinotecan that provides forsustained exposure of irinotecan, and the active metabolite SN-38 in thetumor to a higher proportion of cells during the more sensitive S-phaseof the cell cycle. MM-398 is a liposomal irinotecan that has shownpromising preclinical and clinical activity in a range of cancer types,and was recently approved in the United States in combination with5-FU/LV for patients with metastatic adenocarcinoma of the pancreasafter disease progression following gemcitabine-based therapy. Comparedwith free irinotecan, nal-IRI has an extended PK profile with prolongedlocal tumor exposure of MM-398 and SN-38. Since SN-38 is cleared morequickly from normal tissues than from tumor, it is hypothesized thatdelayed dosing of veliparib relative to MM-398 will allow for theexpected window of maximum irinotecan-induced toxicity to pass in theabsence of concurrent veliparib toxicity. However, the tumor levels ofSN-38 are predicted to be sustained upon subsequent veliparib dosing,therefore maintaining the ability of both drugs to act on tumor tissuesimultaneously and maintain synergy.

One suitable liposomal Top1 inhibitor formulation is liposomalirinotecan available under the brand name ONIVYDE® (irinotecan liposomeinjection) (Merrimack Pharmaceuticals, Inc. Cambridge, Mass.),previously designated “MM-398” prior to FDA approval, and liposomalirinotecan products that are bioequivalent to ONIVYDE. TheONIVYDE/MM-398 (irinotecan liposome injection) includes irinotecan as anirinotecan sucrosofate salt encapsulated in liposomes for intravenoususe. The drug product liposome is a small unilamellar lipid bilayervesicle, approximately 110 nm in diameter, which encapsulates an aqueousspace which contains irinotecan in a gelated or precipitated state, asthe sucrosofate salt. The liposome carriers are composed of1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 6.81 mg/mL;cholesterol, 2.22 mg/mL; and methoxy-terminated polyethylene glycol (MW2000)-distearoylphosphatidylethanolamine (MPEG-2000-DSPE), 0.12 mg/mL.Each mL also contains 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonicacid (HEPES) as a buffer, 4.05 mg/mL; sodium chloride as isotonicityreagent, 8.42 mg/mL, ONIVYDE/MM-398 is believed to include about 80,000molecules of irinotecan in a gelated or precipitated state as asucrosofate salt, encapsulated in a liposome of about 100 nm indiameter.

As used herein, unless otherwise indicated, the dose of irinotecan inONIVYDE/MM-398 refers to the dose of irinotecan based on the molecularweight of irinotecan hydrochloride trihydrate (i.e., “(salt)” dose),unless clearly indicated otherwise. Alternatively, the irinotecan dosein ONIVYDE/MM-393 may also be expressed as the irinotecan free base(i.e., “(base)” dose). Converting a dose based on irinotecan (salt) doseto an irinotecan (base) dose based on irinotecan free base isaccomplished by multiplying the dose based on irinotecan hydrochloridetrihydrate with the ratio of the molecular weight of irinotecan freebase (586.68 g/mol) and the molecular weight of irinotecan hydrochloridetrihydrate (677.19 g/mol). This ratio is 0.87 which can be used as aconversion factor. For example, the 80 mg/m² irinotecan (salt) dose ofONIVYDE/MM-398 refers to the amount of irinotecan based on irinotecanhydrochloride trihydrate, and is equivalent to a 69.60 mg/m² irinotecan(base) dose of ONIVYDE/MM-398 based on irinotecan free base (80×0.87).In the clinic this is rounded to 70 mg/m² to minimize any potentialdosing errors. Similarly, a clinical dose of 120 mg/m² (salt) dose ofONIVYDE/MM-398 (based on the corresponding amount of irinotecanhydrochloride trihydrate providing the same amount of irinotecan freebase) is equivalent to 100 mg/m² (base) dose of ONIVYDE/MM-398 (based onthe actual amount of irinotecan free base administered in the liposomalirinotecan).

ONIVYDE/MM-398 has been shown to improve the pharmacokinetic and safetyprofile of the free irinotecan, through high retention of the irinotecanmolecules within the liposome, by extending the half-life of irinotecanin the plasma, and increased exposure of tumor cells to irinotecancompared with other organs. Table 1 below provides a summary of median(% IQR)*total irinotecan and SN-38 pharmacokinetic parameters observedin patients with solid tumors after administration of ONIVYDE/MM-398 ata dose of 80 mg/m² irinotecan (salt) dose administered once every 2weeks.

TABLE 1 Total Irinotecan SN-38 Dose C_(max) t_(1/2) AUC_(0-∞) V_(d) CLC_(max) t_(1/2) AUC_(0-∞) (mg/m²) [μg/ml] [h]^(†) [h · μg/ml]^(†)[L/m²]^(†) [L h/m²]^(†) [ng/ml] [h]^(†) [h · ng/ml]^(†) 80 38.0 26.81030 2.2 0.077 4.7 49.3 587 (n = 25) (36%) (110%) (169%) (55%) (143%)(89%) (103%) (69%)${*\% \mspace{14mu} {IQR}\text{:}\mspace{14mu} \% \mspace{14mu} {Interquartile}\mspace{14mu} {Ratio}} = {{\frac{{Interquartile} - {range}}{Median} \cdot 100}\; \%}$^(†)t_(1/2), AUC_(0-∞) and V_(d) were only calculated for a subset ofpatients with sufficient number of samples in the terminal phase: n = 23for total irinotecan; n = 13 for SN-38. C_(max): Maximum plasmaconcentration t_(1/2): Terminal elimination half-life AUC_(0-∞): Areaunder the plasma concentration curve extrapolated to time infinityV_(d): Volume of distribution

For ONIVYDE/MM-398, over the dose range of 60 to 180 mg/m², the maximumconcentrations of body total irinotecan and SN-38 increase linearly withdose. The AUCs of total irinotecan increase linearly with dose; the AUCsof SN-38 increase less than proportionally with dose. The half-lives ofboth total irinotecan and SN-38 do not change with dose. In a pooledanalysis from 353 patients, higher plasma SN-38 C_(max) was associatedwith increased likelihood of experiencing neutropenia, and higher plasmatotal irinotecan C_(max) was associated with increased likelihood ofexperiencing diarrhea. Direct measurement of liposomal irinotecan showsthat 95% of irinotecan remains liposome-encapsulated during circulation.The volume of distribution of MM-398 80 mg/m² is 2.2 L/m². The volume ofdistribution of Irinotecan HCl is between 110 L/m² (dose=125 mg/m²) and234 L/m² (dose=340 mg/m²). The plasma protein binding of MM-398 is<0.44% of the total irinotecan in MM-398. The plasma protein binding ofirinotecan HCl is 30% to 68% and approximately 95% of SN-38 is bound tohuman plasma proteins. The plasma clearance of total irinotecan fromMM-398 mg/m² is 0.077 L/h/m² with a terminal half live of 26.8 h.Following administration of irinotecan HCl 125 mg/m², the plasmaclearance of irinotecan is 13.3 L/h/m² with a terminal half live of 10.4h.

Examples of an effective amount of liposomal irinotecan provided asMM-398 include doses (salt) from about 60 mg/m² to about 120 mg/m²,including doses of 70, 80, 90, 100, 110 or 120 mg/m² (based on theweight of irinotecan hydrochloride trihydrate salt) and doses of 50, 60,70, 80, 95, and 100 mg/m² (based on the weight of irinotecan free base),each given once every two (2) weeks (e.g., on days 1 and 15 of a 28 dayantineoplastic treatment cycle). In some embodiments, the effectiveamount of MM-398 is about 80 mg/m² (salt), optionally administered incombination with 400 mg/m² of leucovorin over 30 minutes, followed byintravenous administration of 2400 mg/m² of 5-fluorouracil as aninfusion over 46 hours. In some embodiments, the effective amount ofMM-398 is about 90 mg/m² (free base).

Liposomal irinotecan MM-398 extends the tumor exposure of thetopoisomerase 1 inhibitor SN-38. MM-398 liposomal irinotecan was foundto be more active than irinotecan in multiple murine xenograph models.The duration of tumor exposure to the topoisomerase 1 inhibitor SN-38above a threshold minimum concentration (e.g., 120 nM) correlated withanti-tumor activity of the liposomal irinotecan. In addition, MM-398liposomal irinotecan can provide prolonged SN-38 tumor durations thatexceed those provided by non-liposomal irinotecan. For example, FIG. 13Bdepicts tumor content of SN-38 in multiple murine cervical cancermodels. Nude mice bearing cervical tumors were injected with a singledose of MM-398 at 10 mg/kg and tumor content of CPT-11 and SN-38 weremeasured by LC-MS. FIG. 16A is a graph showing the tumor SN-38 (nmol/L)measured in tumors after administration of free (non-liposomal)irinotecan (CPT-11) at 50 mg/kg or 100 mg/kg, compared to theadministration of MM-398 (5 mg/kg, 10 mg/kg or 20 mg/kg). The graphdepicts the prolonged accumulation of SN-38 (concentration) measured ina tumor after liposomal irinotecan (MM-398) administration compared toother organs, obtained using a using HT-29 colorectal cancer (CRC) tumorxenograft-bearing mice. FIG. 16B is a graph showing levels of tumorgrowth inhibition as a function of time of SN-38 concentration requiredto yield tumor response. Levels of SN-38 of 120 nM were identified asthe SN-38 tumor concentration required to yield tumor response. The invitro IC50 for SN-38 effect on cell line can be used as an in vivothreshold (GI50 for HT-29 was observed to be about 60 nM). MM-398liposomal irinotecan was observed to prolong the duration of SN-38exposure at doses of 10 mg/kg and 20 mg/kg.

PARP Inhibitors

PARPs are a family of enzymes involved in DNA repair that act via twomechanisms: catalytic inhibition and trapping of PARP-DNA complexes, andinhibition of this repair pathway can result in cell death following DNAdamage. In preferred embodiments, combining PARP inhibitors with Top1inhibitors results in increased efficacy in the clinic compared toeither agent alone. While it has been demonstrated that synergismbetween PARP inhibitors and Top1 inhibitors is due to PARP catalyticinhibition, and does not involve PARP trapping, this promisingpreclinical activity has given rise to unacceptable toxicity in theclinic for these combinations.

The PARP inhibitor can be selected from compounds that inhibitPoly(ADP-ribose) polymerase (PARP), a family of enzymes involved in DNArepair. Preferably, the PARP inhibitor is a compound that acts via twomechanisms: catalytic inhibition and trapping of PARP-DNA complexes. ThePARP inhibitor can be one or more clinically available PARP inhibitorcompounds (e.g. talazoparib, niraparib, olaparib, and veliparib, amongothers), including compounds that can act via both mechanisms, althoughto different degrees. For example, niraparib is much more potent at PARPtrapping than veliparib, whereas they both exhibit similar PARPcatalytic activity. The PARP inhibitor can be selected from one or morecompounds selected from the group consisting of talazoparib, niraparib,olaparib, veliparib, iniparib, rucaparib, CEP 9722 or BGB-290. In afurther embodiment, the PARP inhibitor is veliparib, olaparib, rucaparibor niraparib. In another embodiment, the PARP inhibitor is veliparib, orolaparib. The PARP inhibitor can be veliparib administered afterliposomal irinotecan. The PARP inhibitor can be olaparib administeredafter liposomal irinotecan

Olaparib is indicated as monotherapy in patients with deleterious orsuspected deleterious germline BRCA mutated (as detected by anFDA-approved test) advanced ovarian cancer who have been treated withthree or more prior lines of chemotherapy. The recommended dose ofolaparib for this indication is 400 mg (eight 50 mg capsules) takentwice daily, for a total daily close of 800 mg. Patients taking olaparibare instructed to avoid concomitant use of strong and moderate CYP3Ainhibitors and consider alternative agents with less CYP3A inhibition.If the inhibitor cannot be avoided, reduce the Lynparza dose to 150 mg(three 50 mg capsules) taken twice daily for a strong CYP3A inhibitor or200 mg (four 50 mg capsules) taken twice daily for a moderate CYP3Ainhibitor.

The PARP inhibitor can inhibit PARP 1 and/or PARP 2. For example, thePARP inhibitor can be a PARP ½ inhibitor with IC50 of 5 nM/1 nM incell-free assays and 300-times less effective against tankyrase-1 (e.g.,olaparib). The PARP inhibitor can be an inhibitor of PARP 1 and PARP2with Ki of 5.2 nM and 2.9 nM respectively in cell-free assays, andinactive to SIRT2 (e.g., veliparib). The PARP inhibitor can be aninhibitor of PARP 1 with a Ki of 1.4 nM in a cell-free assay, and canalso show binding affinity for other PARP domains (e.g., rucaparib). ThePARP inhibitor can be effective against triple negative breast cancer(TNBC) alone or in combination with other agents. The PARP inhibitor canbe a PARP1 inhibitor with an IC50 of 0.58 nM in a cell free assay thatdoes not inhibit PARG and is sensitive to a PTEN mutation (e.g.,talazoparib). The PARP inhibitor can be a potent and selective tankyraseinhibitor with an IC50 of 46 nM and 25 nM for TNKS 1/2, respectively(e.g., G007-LK). The PARP inhibitor can be a potent inhibitor of PARP 1with a Ki of less than about 5 nM in a cell free assay (e.g., AG-14361).The PARP inhibitor can be a selective inhibitor of PARP 2 with an IC50of 0.3 micromolar, and can be about 27-fold selective against PARP 1(e.g., UPF-1069). The PARP inhibitor can be a potent and selectiveinhibitor with an IC50 for PARP 3 of about 0.89 micromolar, and about7-fold selectivity over PARP 1 (e.g., ME0328). The PARP inhibitor can bean inhibitor of PARP 1 and PARP2 with Ki values of 1 nM and 1.5 nM,respectively.

Preferred examples of PARP inhibitors are provided in the table 2 Abelow, as well as pharmaceutically acceptable prodrugs, salts (e.g.,tosylates) and esters thereof.

TABLE 2A Examples of PARP inhibitors Olaparib (AZD-2281)

Veliparib (ABT-888)

Niraparib (MK04827)

Rucaparib (AG 014699)

Talazoparib (BMN-673)

Iniparib (BSI-201

The dose of the PARP inhibitor and the frequency of dosing can beselected based on various characteristics of the PARP inhibitor,including the pharmacokinetic properties of the compound (e.g.,half-life), prior dosing regimens and patient characteristics.Parameters that can be used in selecting the PARP inhibitor dose includethose listed in Table 2B below.

In addition, patients can be selected to receive treatment combining atopoisomerase inhibitor and a PARP inhibitor. For example, patients canbe selected based on their status in BRCA (e.g. BRCA1, BRCA2),Homologous Recombination Deficiency (HRD), BROCA-HR or other geneticrisk panel analysis of a patient.

TABLE 2B Characteristics of Some PARP inhibitors CharacteristicVeliparib Olaparib Rucaparib Niraparib Talazoparib Molecular 244.3 434.5323.4 320.4 380.4 Weight PARP1 IC50 4.73-5.2 1.94-5 1.4-1.98 2.1-3.80.57-1.2 PAR EC50 5.9 3.6 4.7 2.5 Monotherapy 200-400 mg 300 mg 240-600mg 300 mg 1 mg dosing BID BID BID QD QD CDx BRCA BRCA, HRD HRD BRCA, HRHRD, HR

In the methods of this disclosure, the PARP inhibitor is administered ata therapeutically effective dose (e.g., a dose selected for the PARPinhibitor monotherapy, such as from about 200 mg/day to about 800 mg/dayfor veliparib). In a further embodiment, the PARP inhibitor isadministered twice daily at a dose of from about 100 to about 400 mg forveliparib, rucaparib or olaparib. In some embodiments, 200 mg BID doseof veliparib is administered to patients after (e.g., 3-5 days after)each administration of liposomal irinotecan.

Uses in the Treatment of Cancer

In the methods of this disclosure, the PARP inhibitor is preferablyadministered after an “effective irinotecan plasma clearing interval,”as defined above. The effective plasma clearing interval in the methodsof this disclosure is from about 24 to about 168 hours, including 48hours to about 168 hours. In a further embodiment, the effective plasmaclearing interval is from about 48 to about 96 hours. In a furtherembodiment, the effective plasma clearing interval is 24 hours or 2, 3,4 or 5 days.

In certain embodiments, the MM-398 and the PARP inhibitor areadministered in at least one cycle. A cycle comprises the administrationof a first agent (e.g., a first prophylactic or therapeutic agents) fora period of time, followed by the administration of a second agent(e.g., a second prophylactic or therapeutic agents) for a period oftime, optionally followed by the administration of a third agent (e.g.,a third prophylactic or therapeutic agents) for a period of time and soforth, and repeating this sequential administration, i.e., the cycle. Inone embodiment, the combination of MM-398 and a PARP inhibitor isadministered for at least one cycle. In one embodiment the cycle is a 2week cycle. In another embodiment, the cycle is a 3 week cycle. Inanother embodiment, the cycle is a 4 week cycle. In one embodimentMM-398 is administered at the beginning of the cycle and administrationof a PARP inhibitor (e.g., veliparib) is delayed until at least about24, 48, 72, 96, or 120 hours, after the administration of MM-398. In oneembodiment, MM-398 is administered as part of a 28 day cycle on days 1and 15 and the PARP inhibitor is administered on days 3-12 and on days17-25. In another embodiment, MM-398 is administered as part of a 28 daycycle on days 1 and 15 and the PARP inhibitor is administered on days5-12 and days 19-25.

In some examples, including the protocols in Table 3, the PARP inhibitoris not administered within 3 days of the administration of liposomaltopoisomerase 1 inhibitor such as MM-398 liposomal irinotecan (i.e., thePARP inhibitor is only administered on days that are both at least 2, 3,4 or 5 days after the administration of the liposomal topoisomerase 1inhibitor, and 2, 3, 4 or 5 days prior to the next administration of theliposomal topoisomerase 1 inhibitor). Table 3 shows dose timingprotocols for administering a therapeutically effective amount of a PARPinhibitor and liposomal irinotecan on certain days of a 28-dayantineoplastic treatment cycle.

TABLE 3 Examples of 28-day Treatment Cycles PARP inhibitor LiposomalIrinotecan Protocol given on days given on days  1 3-12; 17-25 1, 15  24-12; 17-25 1, 15  3 5-12; 17-25 1, 15  4 6-12; 17-25 1, 15  5 3-12;18-25 1, 15  6 4-12; 18-25 1, 15  7 5-12; 18-25 1, 15  8 6-12; 18-25 1,15  9 3-12; 19-25 1, 15 10 4-12; 19-25 1, 15 11 5-12; 19-25 1, 15 126-12; 19-25 1, 15

In some examples, the PARP inhibitor is administered on one or more ofdays of a 28-day antineoplastic treatment cycle. For example, the PARPinhibitor can be administered on one or more of days 3, 4, 5, 6, 8, 9,10, 11 and 12 and 19, 20, 21, 22, 23, 24 and 25 of the 28-dayantineoplastic treatment cycle when the liposomal irinotecan (e.g.,MM-398) is administered once every two weeks, or on days 1 and 15 of the28-day antineoplastic treatment cycle.

Methods of treatment and therapeutic uses of PARP inhibitors andtopoisomerase inhibitors (e.g., liposomal irinotecan) disclosed hereinare useful in the treatment of various forms of cancer Preferably, thecancer includes a diagnosed solid tumor. In some examples, the cancer(e.g., solid tumor) is of a tumor type with one or more DNA repairpathway deficiencies, such as breast and ovarian tumors with BRCA1 orBRCA2 mutations.

In the methods of this disclosure, the cancer is cervical cancer,ovarian cancer, breast cancers including triple negative breast cancer(TNBC), non-small cell lung cancer (NSCLC), small cell lung cancer(SCLC), gastric cancer, pancreatic cancer, colorectal cancer, or aneuroendocrine tumor.

The methods of this disclosure can further comprise administering to thepatient one or more additional agents including, but not limited, toanti-emetics such as a 5-HT3 antagonist; agents for treating ofdiarrhea, such as loperamide; dexamethasone; or other chemotherapeuticagents.

In one embodiment, the methods of the present disclosure result in apathologic complete response (pCR), complete response (CR), partialresponse (PR) or stable disease (SD). In another embodiment thecombination therapy with MM-3898 and a PARP inhibitor, e.g., veliparib,results in therapeutic synergy.

Further aspects include providing an existing standard of care therapyto the patients, which may or may not include treatment with appropriatesingle agents. In some instances, the standard of care may includeadministration of a PARP inhibitor compound.

Thus, in one aspect, the present disclosure provides a method oftreating a patient with cancer and having a tumor, the methodcomprising:

-   -   i. parenterally (e.g., intravenously) administering to the        patient an effective amount of an irinotecan liposomal        formulation; and    -   ii. administering to the patient an effective amount of a PARP        inhibitor wherein the PARP inhibitor is administered after an        effective irinotecan plasma clearing interval.

The present disclosure provides a method of treating a patient withcancer and having a tumor, the method comprising a treatment regimenthat may be repeated at weekly or longer intervals (e.g., Q2W, Q3W, orQ4W), each instance of the treatment comprising:

-   -   i. intravenously administering to the patient an effective        amount of an irinotecan liposomal formulation of a Top1        inhibitor such as irinotecan, topotecan, lurtotecan, indotecan,        and indimitecan; and    -   ii. administering to the patient and effective amount of a PARP        inhibitor wherein the PARP inhibitor is administered after an        interval following completion of the administration of the Top1        inhibitor, e.g., an effective irinotecan plasma clearing        interval.

In a further embodiment, the method comprises:

-   -   i. intravenously administering to the patient an effective        amount of an irinotecan liposomal formulation having a terminal        elimination half-life of about 26.8 hours and a maximal        irinotecan plasma concentration of about 38.0 micrograms/ml; and    -   ii. administering to the patient and effective amount of a PARP        inhibitor wherein the PARP inhibitor is administered after an        interval of 24 hours or up to three days following completion of        the administration of the irinotecan.

EXAMPLES

The following non-limiting examples illustrate the methods of thepresent disclosure.

Example 1 In Vitro Studies

In vitro studies were performed testing combinations of various PARPinhibitors and topoisomerase inhibitors liposomal irinotecan and SN-38.

FIGS. 1A-1D show line graphs that depict cervical cancer cell viabilityfollowing treatment with SN-38 and/or various PARP inhibitors. Unlessotherwise indicated, the data in each of these figures was obtained bymeasuring cell viability of 5 different cervical cancer cells (MB-180 inFIG. 1A, MS-751 in FIG. 1B, C-33A in FIG. 1C, SW756 in FIG. 1D and SiHain FIG. 1E) with 1000 cells/well in a 384 well plate treated with SN-38(topoisomerase 1 inhibitor) and/or one of 3 different PARP inhibitors(veliparib, niraparib, or olaparib) at 0.33 micrograms/mL) for 24 hours,followed by washing and incubation for an additional 72 hours with freshmedia.

The combination of the topoisomerase 1 inhibitor SN-38 and various PARPinhibitors (veliparib, olaparib and rucaparib) were tested in vitro withvarious small cell lung cancer (SCLC), pancreatic cancer and breastcancer cell lines. At 2 nM SN-38 concentration, an additive/synergisticgrowth inhibition of the cancer cells was observed in combination witholaparib, veliparib and rucaparib (with veliparib observed to beslightly less potent in the combination with SN-38 than olaparib andrucaparib). At all concentrations tested, the static growth of thecancer cell population was achieved. FIGS. 2A-2E are graphs showing theresults of in vitro experiments evaluating combinations of thetopoisomerase 1 inhibitor SN38 with various PARP inhibitors, formattedaccording to the tables 4-5 below (plates of 5,000 cells/well, 100microliters per well; drugs added with 20× at 10 microliters per drug,top up to 100 microliters total with DMEM; then initiate scan every 4hours up to 68 hours).

TABLE 4 TNBC Small Cell Lung Cancer Pancreatic Cancer MDA- TreatmentDMS-114 NCI-H1048 CFPAC-1 BxPC-3 MB-231 SN-38 & Plate 1 Plate 2 Plate 3Plate 4 Plate 5 Olaparib SN-38 & Plate 1 Plate 2 Plate 3 Plate 4 Plate 5Rucaparib SN-38 & Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Veliparib

TABLE 5 Target Concentrations Active Range based Estimated tumor DoseConc' Drug on XTC008 range (nM) Level (nM) SN-38 1-50 nM 3-163 nM (398):S1 2 IRI < 200 nM S2 5 S3 10 S4 20 S5 50 Olapano 100)-10000 nM   8000 nMO1 2000 O2 4000 O3 8000 Veliparib 1000-10000 nM >2000 nM V1 2000 V2 4000V3 8000 Rucaparib 1-100 nM (Panc) <6000 nM R1 2000 R2 4000 R3 8000

Additive/synergistic effects were observed between SN-38 at 2 nMcombined with the tested PARP inhibitors olaparib, veliparib andrucaparib with DMS-114 SCLC cells. FIG. 2A is a graph showing theresults of in vitro measurement of % cell number over time for DMS-114small cell lung cancer cells treated with the topoisomerase inhibitorSN-38 and the PARP inhibitor rucaparib.

The NCI-H1048 SCLC cells were slow-growing and very sensitive tocombinations of olaparib and rucaparib with SN-38 at 2 nM. FIG. 2B is agraph showing the results of in vitro measurement of % cell number overtime for NCI-H1048 small cell lung cancer cells treated with thetopoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib.

Additive/synergistic effects were observed between SN-38 at 2 nMcombined with the tested PARP inhibitors olaparib, veliparib andrucaparib with CFPAC-1 pancreatic cancer cells. FIG. 2C is a graphshowing the results of in vitro measurement of % cell number over timefor CFPAC-1 pancreatic cancer cells treated with the topoisomeraseinhibitor SN-38 and the PARP inhibitor rucaparib.

FIG. 2D is a graph showing the results of in vitro measurement of % cellnumber over time for BxPC-3 pancreatic cancer cells treated with thetopoisomerase inhibitor SN-38 and the PARP inhibitor rucaparib. FIG. 2Eis a graph showing the results of in vitro measurement of % cell numberover time for MDA-MB-231 triple negative breast cancer (TNBC) cancercells treated with the topoisomerase inhibitor SN-38 and the PARPinhibitor rucaparib.

FIG. 13A depicts the in vitro activity of SN-38 in cervical models.Cervical cells lines were treated with veliparib and SN-38 at either thesame time or with scheduling with Veliparib being added 24 h afterSN-38, and cell viability was measured using CTG assay.

Example 2 Pre-Clinical Dose Tolerability Studies

Various pre-clinical in vivo experiments were conducted to evaluatedelayed dosing of veliparib relative to liposomal irinotecan canalleviate systemic toxicity, including a pre-clinical dose tolerabilitystudy. The combination of veliparib and irinotecan has been plagued bydose-limiting toxicities that have prevented this combination from beingdosed at high (effective) doses of each drug, thereby limiting itsclinical utility. To address this problem, pre-clinical studiesevaluated administering a liposomal preparation of a topoisomerase 1inhibitor, followed by the administration of a PARP inhibitor at least 1day (preferably 2-3 days) after the day on which the liposomaltopoisomerase 1 inhibitor was administered.

The advantage of dosing with MM-398 compared to free irinotecan is theextended PK profile and prolonged local tumor exposure of MM-398. SinceSN-38 is cleared more quickly from normal tissues than from tumor,delayed dosing of veliparib (e.g. starting veliparib dosing a few daysafter MM-398 administration) allows for the window of maximumirinotecan-induced toxicity to pass in the absence of concurrentveliparib toxicity. However, the tumor levels of SN-38 are sustainedlonger than in healthy tissue, such that upon PARP inhibitor dosingsubsequent to liposomal Top1 inhibitor (e.g., MM-398) administration,both drugs will act on tumor tissue simultaneously.

To demonstrate that delayed dosing of veliparib relative to nal-IRI canalleviate systemic toxicity, a pre-clinical dose tolerability study wasperformed. Mice were dosed chronically with nal-IRI once weekly atvarious doses on Day 1, while veliparib was dosed once daily at a fixeddose for 3 consecutive days each week (either on Days 2-4, Days 3-5, orDays 4-6), and body weight was followed as a gross measure of toxicity.All mice were dosed chronically once weekly on day 1, with veliparibsubsequently dosed for 3 consecutive days either on days 2-4, days 3-5,or days 4-6. Mice were weighed daily and bodyweight gain is indicated onthe Y-axis. Weight loss is indicative of intolerability of thecombination. Notably, the highest (50 mg/kg) dose of MM-398 liposomalirinotecan was best tolerated (i.e., lowest measured reduction in %bodyweight observed over the experiment) when the veliparib wasadministered on days 4, 5 and 6 (FIG. 5C). Similarly, the combination ofveliparib and MM-398 was best tolerated at lower MM-398 liposomalirinotecan doses when the veliparib was only administered on days 4, 5,and 6 after MM-398 administration. Toxicity of the combination was seenat the highest doses of MM-398 when given in close proximity to theveliparib doses (FIG. 5A). However, this toxicity could be alleviatedeither by dose reducing MM-398 or delaying the start of veliparibdosing, whereby the highest dose of MM-398 could be successfully dosedwith veliparib if given on Days 4-6 following Day 1 dosing of MM-398.The Day 4-6 veliparib dosing schedule (following day 1 dosing of MM398)was followed in subsequent efficacy studies which demonstrated synergyof the combination in two cervical cancer tumor xenograft models, inwhich veliparib alone was not efficacious (FIG. 7A) and a second modelin which neither MM-398 or veliparib were efficacious as single agents(FIG. 7B), however the combination demonstrated tumor growth inhibition(FIG. 7B).

To exemplify an embodiment demonstrating that delayed dosing of olaparibrelative to MM-398 can alleviate systemic toxicity, a pre-clinical dosetolerability study was performed. FIG. 4 depicts a graphicalrepresentation of a murine tolerability study design comparing MM-398and olaparib as a monotherapy or in combination using a fixed dose ofMM-398 and varying doses of olaparib, with various dosing schedules fordifferent groups: Group 1: MM-398 alone IV (10 mg/kg); Group 2: olaparibalone oral (200 mg/kg); Group 3: MM-398 (d1)+olaparib (200 mg/kg, d1-5);Group 4: MM-398 (d1)+olaparib (150 mg/kg, d1-5; Group 5: MM-398(d1)+olaparib (200 mg/kg, d1-4); Group 6: MM-398 (d1)+olaparib (200mg/kg, d2-5); Group 7: MM-398 (d1)+olaparib (265 mg/kg, d3-5); group 8:DMSO alone oral (FIGS. 6A-6D). Mice that received monotherapy of MM-398,olaparib were dosed 5× weekly. Mice that received a combination of aconstant concentration of MM-398 (10 mg/kg) and varying concentration ofolaparib were dosed in varying schedules: Group 3: MM-398 (d1)+olaparib(200 mg/kg, d1-5); Group 4: MM-398 (d1)+olaparib (150 mg/kg, d1-5; Group5: MM-398 (d1)+olaparib (200 mg/kg, d1-4); Group 6: MM-398 (d1)+olaparib(200 mg/kg, d2-5); Group 7: MM-398 (d1)+olaparib (200 mg/kg, d3-5). Micewere monitored for treatment dependent toxicities by charting bodyweight and percent survival. Addition of olaparib seemed to be moretoxic as compared to monotherapy, however delaying start of olaparibadministration to d3 seemed to decrease olaparib specific toxicity ascompared to concurrent therapy. Mice were dosed chronically with MM-398once weekly at various doses on Day 1, while olaparib was dosed oncedaily at a weekly fixed dose for 5, 4 or 3 consecutive days each week(either on Days 1-5, Days 1-4, Days 2-5 or Days 3-5), and body weightand percent survival were followed as a gross measure of toxicity.Toxicity of the combination was seen at the highest doses of MM-398 whengiven in close proximity to the olaparib doses (FIG. 4). However, thistoxicity could be alleviated either by delaying the start of olaparibdosing, whereby the highest dose of MM-398 could be successfully dosedwith olaparib if given on Days 3-5 following Day 1 dosing of MM-398.

Mice were dosed chronically with MM-398 once weekly at various doses onDay 1, while veliparib was dosed once daily at a fixed dose for 3consecutive days each week (either on Days 2-4, Days 3-5, or Days 4-6)and body weight was followed as a gross measure of toxicity. Toxicity ofthe combination was seen at the highest doses of nal-IRI when given inclose proximity to the veliparib doses. However, this toxicity could bealleviated either by dose reducing nal-IRI or delaying the start ofveliparib dosing. This dosing schedule was followed in subsequent mouseefficacy studies which demonstrated synergy of the combination in twocervical cancer tumor xenograft models, in which veliparib alone was notefficacious, and a second model in which neither nal-IRI or veliparibwere efficacious as single agents, however the combination demonstratedtumor growth inhibition.

The tolerability of the combination of MM398 in a mouse model on day 1was evaluated in combination with the administration of veliparib ondays 1-3, days 2-4 and days 3-5. The tolerability of the combinedregimen in mice (measured by change in percent bodyweight over 20 days)increased as the first administration of the veliparib occurred on day 2and day 3, with day 3 initial veliparib dosing providing the mosttolerated dosing schedule. FIG. 8A is a graph that further depicts thein vivo tolerability of the 50 milligrams/kilogram (mpk) dose of MM-398on day 1 in combination with 50 mg/kg veliparib given on days 1, 2, and3; or days 2, 3, and 4; or days 3, 4, and 5 after administration of theMM-398, as reflected in percent change in body weight with an adjustedlower limit. FIG. 8B is a graph that further depicts the in vivotolerability of the 28 mpk dose of MM-398 on day 1 in combination with50 mg/kg veliparib given on days 1, 2, and 3; or days 2, 3, and 4; ordays 3, 4, and 5 after administration of the MM-398, as reflected inpercent change in body weight with an adjusted lower limit.

FIG. 12 is a graph showing that treatment of mice with the combinationof MM-398 with veliparib in C33A xenograft model described in Example 4also lead to decreases in body weight as compared to administration ofeither drug alone.

These studies demonstrated that this toxicity could be alleviated bydelaying the start of PARP inhibitor dosing, preferably by 2-3 daysafter the day on which liposomal irinotecan was administered. A dosingschedule where the PARP inhibitor was only administered on dayssubsequent to administration of liposomal irinotecan was followed inmouse efficacy studies (Example 3) demonstrating therapeutic synergy ofthe combination of a PARP inhibitor and liposomal irinotecan in twocervical cancer tumor xenograft models (in which veliparib alone was notefficacious, and a second model in which neither MM-398 or veliparibwere efficacious as single agents, however the combination demonstratedtumor growth inhibition).

Example 3 Pre-Clinical Efficacy of Liposomal Irinotecan

In vivo tumor xenograft studies demonstrated that the efficacy ofliposomal irinotecan is greater than free irinotecan. In addition, invivo tumor xenograft studies demonstrated MM-398 is related to high CESactivity and/or high tumor levels of CPT-11 following dosing withMM-398. Additionally, MM-398 has demonstrated superior activity comparedto equivalent dosing of free irinotecan in several pre-clinical modelsincluding breast, colon, ovarian, and pancreatic tumor xenograft models.

Liposomal irinotecan (MM-398) has greater efficacy in various cancermodels, compared to non-liposomal irinotecan. Cancer cells wereimplanted subcutaneously in mice; when tumors were well established andhad reached mean volumes of 200 mm3, IV treatment with free irinotecan,MM-398 or control was initiated. The doses of free and nanoliposomalirinotecan used in each study are indicated above, with dose time pointsindicated by arrows. Tumor permeability as well as tumor tissuecarboxylesterase (CES) activity, which is responsible for the enzymaticconversion of CPT-11 to SN-38, are predicted to be critical factors forlocal tumor exposure of SN-38 following MM-398 dosing. In vivo tumorxenograft studies have demonstrated that efficacy of MM-398 is relatedto high CES activity and/or high tumor levels of CPT-11 following dosingwith MM-398. Additionally, MM-398 has demonstrated superior activitycompared to equivalent dosing of free irinotecan in several pre-clinicalmodels including breast, colon, ovarian, and pancreatic tumor xenograftmodels.

Example 4 Pre-Clinical Activity of Liposomal Irinotecan and PARPInhibitors

Referring to FIG. 7A and FIG. 7B, the antitumor activity of MM-398 wasstudied in combinations with veliparib (PARPi) in multiple cervicalxenograft models. In this study. MS-751 and C33A xenograft models ofcervical cancer were employed to probe the effect of administeringsuboptimal doses of MM-398 in combination with the PARP inhibitorveliparib. Differential tissue levels of MM-398 at 24 and 72 hoursindicated that MM-398 and the active metabolite SN-38 cleared fasterfrom the liver, spleen, colon, and plasma, than from tumors. Thecombination of veliparib and MM-398 gave improvements in key PDbiomarkers (cleaved caspase and yH2AX) when compared to veliparib orMM-398 alone. FIGS. 7A and 7B show that the combination ofMM-398+veliparib is synergistic. Two different cervical cancer xenograftmodels were utilized to study the efficacy of MM-398 dosed once weeklyon Day 1 (arrows), veliparib dosed at 50 mg/kg orally once daily for 3consecutive days on Days 4-6 of each week, or the combination dosed onthe same schedule as the single agent treatments combined. (A) MS751cervical cancer xenograft model using MM-398 dosed at 5 mg/kg and (B)C33A cervical cancer xenograft model using MM-398 dosed at 2 mg/kg. Inthe study, control mice were the same strain, and were harvested priorto tested mice (slightly younger). Data is not presented for miceremoved from study for weight loss or for mice removed unintentionallybefore end date.

Cervical MS-751 Xenograft Model

The MS-751 Xenograft Model details are summarized in Table 6.

TABLE 6 Mouse strain: Nude (Tacoma) Tumor Cervical MS-751, C33AInoculation: 5*10{circumflex over ( )}6 (s.c.) in 30% MG Drug: MM-39(iv) + Veliparib (oral) Animal per Dose Groups: group: (mpk) 1 Saline 102 MM-398 10 5 3 veliparib/oral 10 50 3/4/5th day 4 MM-398 + veliparib 105 + 50 3/4/5th day

FIG. 9A shows that minor volume decreased when MM-398 (5 mpk dose) wasadministered in combinations with veliparib in the MS751 xenograft model(p=0.03) as compared to administration of either drug alone. FIG. 9Bshows that percent survival was better for mice treated with MM-398 (5mpk dose) in combinations with veliparib in MS751 xenograft model ascompared to treatment with either drug alone either drug administeredalone. FIG. 9C shows that treatment with the combination of MM-398 withveliparib in MS751 xenograft model lead to decreases in body weight ascompared to administration of either drug alone.

C33A Cervical Xenograft Model

The C33A Xenograft Model details are summarized in Table 7.

TABLE 7 Mice: Female, Ncr Nudes (Taconic), 5-6 weeks. Cell Lines: C33 ATumor Inoculation: 5 × 10⁶ in 100 μl Matrigel (30 vol %) sc 15 mice pera cell line Groups: Dose, mpk: MM-398 alone 2 Veliparib alone 50MM-398 + Veliparib (3-4-5 d) 2 + 60 End-life Collection: 72 h afterfirst injection Frozen (Tumor, Liver, Spleen, Plasma) FFPA (Tumor)Analysis: gamma H2AX and cleaved caspase/Tunnel in FFPE (Lia) CPT-11 andSN-38 in all tissues or MM-398 flash frozen only (Roswell)

FIG. 10 shows that the combination of MM-398 with veliparib in the C33Axenograft model leads to decreases in tumor volume as compared to eitherdrug alone administered alone. FIG. 11 shows that percent survival wasbetter for mice MM-398 (5 mpk dose) in combinations with veliparib inC33A xenograft model as compared to either drug administered alone.

Example 5 Clinical Use of Liposomal Irinotecan and PARP InhibitorsClinical Use of Liposomal Irinotecan and Veliparib

This is a Phase 1 human dose escalation study to characterize thesafety, tolerability, MTD and PK of MM-398 in combination with veliparibin order to determine an optimal combination dose and schedule that willbe identified as the recommended Phase 2 dose. The following schematicoutlines two different schedules of veliparib dosing that will beexplored in combination with MM-398 bi-weekly dosing:

MM-398 will be administered by intravenous (IV) infusion over 90 minutesat a dose of 80 mg/m² every two weeks. MM-398 is administered byintravenous (IV) infusion over 90 minutes at a dose of 80 mg/m² (salt)irinotecan once every two weeks (days 1 and 15 of each 28-day treatmentcycle). Veliparib is co-administered orally twice daily by the patientat home according to the following schedule:

Table 8 Veliparib MM-398 Dose Dose Dose Velliparib Dose (salt) Level¹(mg BID) Days (mg/m² q2w) 1 100 Day 5-12; 19-25 80, Day 1, 15 2 200 Day5-12; 19-25 80, Day 1, 15 3 200 Day 5-12; 17-25 80, Day 1, 15 4 300 Day5-12; 19-25 80, Day 1, 15 5 400 Day 5-12; 19-25 80, Day 1, 15¹Additional dose levels and alternate dosing schedules may be exploredupon agreement of Sponsor, Medical Monitor and Investigators. ** Afterthe MTD is reached, and for the first cycle only, we plan to enrollapproximately 18 patients obtain tumor biopsies according to the schemaoutlined in the correlates section below.

The study will enroll 3 patients per dose cohort following a traditional3+3 dose escalation design. Dose limiting toxicities (DLTs) will beevaluated during the first cycle of treatment (28 days) in order todetermine the MTD. If there are no DLTs within the safety evaluationperiod, then the next cohort can be initiated following agreementbetween the Investigators and Medical Monitor. If a DLT occurs, then thecohort will be expanded to 6 patients. If 2 or more patients have DLTswithin a given dose level, then the dose will not be escalated further;however, lower doses may be explored. Additional dosing schedules mayalso be explored depending on the safety, tolerability, and PK observed.

Given that these individual therapies have been studied in previousclinical trials, it is important that the safety assessment takes intoaccount the expected safety profile of the standard dose regimens. Forall treatment regimens, any toxicity that is related to diseaseprogression will not be considered a DLT. The following events,occurring during cycle 1 of the study combination, will be consideredDLTs if deemed drug-related:

-   -   grade 3 or 4 neutropenia complicated by fever≥38.5° C. (i.e.        febrile neutropenia) and/or documented infection;    -   grade 4 neutropenia that does not resolve within 7 days despite        optimal therapy (withholding study drug and GCSF        administration);    -   grade 4 thrombocytopenia that does not resolve within 7 days or        any grade 3-4 thrombocytopenia complicated with hemorrhage;    -   grade 4 anemia that does not resolve within 7 days despite        optimal therapy (withholding study drug and red blood cell        transfusions);    -   inability to begin subsequent treatment course within 14 days of        the scheduled date, due to study drug toxicity;    -   any grade 3-4 non-hematologic toxicity (except        fatigue/asthenia<2 weeks in duration; vomiting or diarrhea        lasting less than 72 hours whether treated with an optimal        anti-emetic or anti-diarrheal regimen or not; or alkaline        phosphatase changes).    -   ≥grade 2 seizure

Patients will be treated until disease progression as determined byRECIST v1.1 criteria evaluated by CT scan every 8 weeks from first doseof study drug. The inclusion and exclusion criteria for the clinicaltrial are summarized in the table 9 below.

TABLE 9 Inclusion Criteria Exclusion Criteria Patients must havehistologic or Active CNS metastasis cytologic confirmation of cancer forClinically significant GI disorders, which there is no known standardincluding history of small bowel therapy capable of extending lifeobstruction unless the obstruction expectancy. was a surgically treatedremote ECOG Performance Status 0 or 1 episode Tumor lesion(s) amenableto multiple Prior irinotecan therapy; or pass percutaneous biopsies andpatient topotecan therapy or bevacizumab willing to undergo requiredpre- and therapy within 6 months of first post-treatment biopsies doseof study treatment Must have adequate: Prior chemotherapy or biologicalBone marrow function therapy within 3 weeks, or within a ANC > 1,500cells/μl without the time interval less than 5 half-lives use ofhematopoietic growth of the agent, prior to first dose of factors studytreatment Platelet count > 100,000 cell/μl Prior radiotherapy within 4weeks Hemoglobin > 9 g/dL of first dose of study treatment Hepaticfunction Patients who have had radiation to Normal serum total bilirubinthe pelvis or other bone marrow- AST and ALT ≤2.5 × ULN (≤5 × bearingsites will be considered on ULN is acceptable if liver a case by casebasis and may be metastases are present) excluded if the bone marrowRenal function reserve is not considered adequate Serum creatinine ≤1.5× ULN (i.e. radiation to >25% of bone Normal ECG marrow) ≥18 years ofage Known hypersensitivity to Able to understand and sign informedMM-398 consent Active infection Prior PARP inhibitor therapy is Pregnantor breast feeding allowed Willing to undergo pre-treatment ferumoxytolMRI (patients will be excluded from undergoing ferumoxytol MRI if theyhave evidence of iron overload, a known hypersensitivity to ferumoxytolor any other IV iron product, a documented history of multiple drugallergies, or those for whom MRI is otherwise contraindicated, includingclaustrophobia or anxiety related to undergoing MRI)

The dose escalation portion of the trial may require up to 30 patientsif 6 patients are required at each of 5 dose levels. An additional 18patients may be used to explore the effect of veliparib on the biologiccorrelates. Thus, the accrual ceiling will be set at 48 patients.

The study is proposed to include all solid tumor types, however,particular indications that are of high interest for this study includesthe following: cervical cancer, ovarian cancer, triple negative breastcancer (TNBC), non-small cell lung cancer (NSCLC), small cell lungcancer (SCLC), gastric cancer, pancreatic cancer, and neuroendocrinetumors.

The methods and uses herein can also be applied to other tumor suitabletypes including those noted for increased frequency of DNA damageresponse (DDR) pathway deficiencies (or ‘BRCAness’) found in sporadictumors, which are predicted to be sensitive to PARP inhibitors. Asmentioned previously, BRCA1 or BRCA2 deficiencies, found particularly intriple negative breast cancer and high-grade serous ovarian cancer,sensitize cells to PARP-inhihitors. Likewise, loss of function of othergenes and proteins involved in DDR pathways, including the endonucleaseXPF-ERCC1, the homologous recombination repair proteins meioticrecombination protein 11 (MRE11) and Fanconi anemia pathway (FANC)proteins, also sensitize cells to PARP inhibitors. Fanconi anemiapathway deficiencies have been demonstrated in lung, cervical, andbreast and ovarian cancers. These and other DDR pathway deficiencies maybe predictive biomarkers for PARP inhibitor therapy, and will beexplored retrospectively in this study. Veliparib, specifically, hasalso demonstrated clinical activity in a number of indications,including BRCA-positive and BRCA wild-type breast and ovarian cancer, aswell as gastric cancer in combination with FOLFIRI. For the proposedstudy, indications were chosen not only for their high unmet medicalneed, but for potential sensitivity to irinotecan and/or veliparib basedon the aforementioned pre-clinical and/or clinical experience. While thePARP inhibitor olaparib has recently been FDA approved as a monotherapyin BRCA+ ovarian cancer, this study will not limit treatment in theovarian patient population to BRCA+ patients, as this is a phase I studyof a combination therapy and may retrospectively identify patients withother DDR pathway deficiencies in addition to BRCA.

Use of Liposomal Irinotecan and Olaparib

MM-398 is administered by intravenous (IV) infusion over 90 minutes at adose of 80 mg/m² (based on the corresponding amount of irinotecanhydrochloride trihydrate, equivalent to 70 mg/m² irinotecan free base)every two weeks. Olaparib is co-administered orally twice daily by thepatient at home according to the following schedule (Table 10).

TABLE 10 Olaparib Dose Dose Oaparib Dose MM-398 Dose Level¹ (mg BID)Days (mg/m² q2w)* 1 100 Day 5-12; 19-25 80, Day 1, 15 2 200 Day 5-12;19-25 80, Day 1, 15 3 200 Day 5-12; 17-25 80, Day 1, 15 4 300 Day 5-12;19-25 80, Day 1, 15 5 400 Day 5-12; 19-25 80, Day 1, 15 * = The 80 mg/m²MM-398 dose is based on the corresponding amount of irinotecanhydrochloride trihydrate (equivalent to 70 mg/m² based on irinotecanfree base).

Example 6 Measuring Phosphorylated H2AX in Tumor Biopsies

Phosphorylated H2AX (γ-H2AX) plays an important role in the recruitmentand/or retention of DNA repair and checkpoint proteins such as BRCA1,MRE11/RAD50/NBS1 complex, MDC1 and 53BP1. DNA damage has been shown toincrease H2AX phosphorylation in cancer cells following exposure tocamptothecins. If the PARP inhibitor compound(s) is/are able to increasethe degree of DNA damage due to irinotecan from MM-398, it may bedetectable by measurement of H2AX phosphorylation. An immunofluorescenceassay was used in previous clinical studies. Patient peripheral bloodmononuclear cells (PBMCs), hair follicles, and/or tumor biopsy sampleswill be collected if there is readily accessible disease. Theassociation between the pharmacodynamic response measured by γ-H2AXlevel can be assessed by Fisher's test or the Wilcoxon rank sum test, asappropriate; this evaluation will be done at the MTD+/−a maximum of 2dose levels (FIG. 14).

TABLE 11 Schedule for biopsies and surrogate samples PARPi MM-398 Biopsyin Dose Dose PARPi Dose Dose am for Level (mg BID) Days (mg/m² q2w) PDmarker 1 100 Day 5-12; 19-25 80, Day 1, 15 — 2 200 Day 5-12; 19-25 80,Day 1, 15 — 3 200 Day 3-12; 17-25 80, Day 1, 15 Days 1, 5, 19 4 300 Day3-12; 17-25 80, Day 1, 15 Days 1, 5, 19 5 400 Day 3-12; 17-25 80, Day 1,15 Days 1, 5, 19 Confirm A MTD Day 3-12; 19-25 80, Day 1, 15 Days 1, 5,19 B MTD Day 5-12; 17-25 80, Day 1, 15 Days 1, 5, 19

Example 7 Administering and Detecting Ferumoxytol to Predict Depositionof Topoisomerase Inhibitor from Liposomal Irinotecan

FIGS. 15A-15C show that FMX MRI may be a predictive tool for tumorresponse to MM-398. FIG. 15A is a schematic showing that MM-398 and FMXhave similar properties, including 1) extended PK, 2) the ability todeposit in tumor tissues through the EPR effect (i.e. leakyvasculature), and 3) uptake by macrophages. Therefore, visualization ofFMX on MRI may be able to predict MM-398 deposition. (B) FMXconcentration of individual patient lesions was calculated using astandard curve from MR images obtained 24 h post-FMX injection. (C) FMXsignal from lesions at 24 h are grouped relative to the median valueobserved in the FMX MRI evaluable lesions and compared to the bestchange in lesion size based on CT scans (data available from 9 patients;total of 31 lesions).

The phase 1 study of MM-398 also examined the feasibility of magneticresonance (MR) imaging to predict tumor-associated macrophage (TAM)content and MM-398 deposition. TAMs appear to play a key role in thedeposition, retention and activation of MM-398 within the tumormicroenvironment. In this clinical study, ferumoxytol (FMX) amicroparticulate preparation of a superparamagnetic iron oxide coatedwith polyglucose sorbitol carboxymethylether) was used as an imagingcontrast agent and MR images were obtained at 1 h, 24 h, and 72 hfollowing FMX injection. FMX is an approved therapy that is indicatedfor the treatment of iron deficiency anemia in adult patients withchronic kidney disease; however a growing number of cancer patientswithout iron deficiency are being administered FMX as an imaging agentto visualize macrophage content and vasculature. Like MM-398, FMX isalso a nanoparticle with a diameter of approximately 17-31 nm. As tumorpermeability was predicted to be an important factor in MM-398 efficacy,FMX was also investigated for use as a surrogate for liposome deposition(FIG. 15A). A benefit of FMX is that this agent helps to identitypatients that are less likely to respond to MM-398 because of poor druguptake. Ferumoxytol as a diagnostic test enables the detection of apatient population that would significantly benefit from MM-398 thatwould otherwise be uncategorized.

The MRI results from a human clinical trial study demonstrated that theamount of FMX depositing in tumor lesions was able to be quantified(FIG. 15B), and it was subsequently shown that a correlation existedbetween tumor lesion ferumoxytol uptake by MRI and response to MM-398(FIG. 15C). This correlation is now being studied further in anexpansion of the Phase 1 study, and is included as a correlative imagingstudy for a trial of MM-398+veliparib.

FMX is an iron replacement product indicated for the treatment of irondeficiency anemia in adult patients with chronic kidney disease.Although not approved as an indication, ferumoxytol has also been usedas an imaging agent in cancer patients and will be utilized as such inthis study. At least 2 days prior to Cycle 1 Day 1 (maximum of 8 daysprior) a single dose of 5 mg/kg FMX will be administered by intravenousinjection. The total single dose will not exceed 510 mg. the maximumapproved single dose of FMX. This dosing schedule is less intense thanthe approved label, which recommends two doses of 510 mg 3 to 8 daysapart; however since FMX is being used as imaging agent in this study asopposed to a replacement product for iron deficiency, a lower dose ismore appropriate. Three MRIs will be performed for each patient over 2days. All patients will have a baseline image acquired prior to the FMXinfusion, and a second image acquired 1-4 h after the end of FMXadministration. All patients will return the following day for a 24 hFMX-MRI using the same protocol and sequences as previously. Eachpatient will be required to complete their FMX-MRIs on the same scannerto reduce inter-scan variability. The body area to be scanned will bedetermined by the location of the patient's disease. Each MRI study willbe evaluated for image quality and signal characteristics of tumors andreference tissue on T1-, T2- and T2*-weighted sequences. Once acompleted set of images from each patient has been received, aqualitative review will be performed and sent to a quantitative lab foranalysis. The data will be analyzed in a similar fashion as describedabove.

TABLE 12 Imaging Correlates Organ(s) Scanned and Correlative ObjectiveImaging Technique Timing of Scans Ferumoxytol (FMX) MRI Sites ofdisease; 3 scans uptake completed approximately 2-6 days prior to Cycle1 Day 1. Scan time points: baseline (immediately prior to FMX infusion)1 h (post-FMX infusion) 24 h (post-FMX infusion) Histone gamma-H2AXImmunofluorescence Tumor biopsy before (Pommier, DTB-CCR; microscopytreatment, and during Doroshow, Leidos) ELISA (in treatment.development) Hair follicles during treatment. PBMC before treatment andduring treatment

Imaging Correlate Study

Patients will be eligible to participate in the FMX imaging study ifthey do not meet any of the following criteria:

-   -   Evidence of iron overload as determined by:        -   Fasting transferrin saturation of >45% and/or        -   Serum ferritin levels >1000 ng/ml    -   A history of allergic reactions to any of the following:        -   compounds similar to ferumoxytol or any of its components as            described in full prescribing information for ferumoxytol            injection        -   any IV iron replacement product (e.g. parenteral iron,            dextran, iron-dextran, or parenteral iron polysaccharide            preparations)        -   multiple drugs    -   Unable to undergo MRI or for whom MRI is otherwise        contraindicated (e.g. presence of errant metal, cardiac        pacemakers, pain pumps or other MRI incompatible devices; or        history claustrophobia or anxiety related to undergoing MRI)

If a patient consents to FMX-MRI, the patient will receive ferumoxytolinfusion and undergo the required FMX-MRI scans approximately 2-6 daysprior to beginning MM-398 treatment (the FMX period). FMX will beadministered at a dose of 5 mg/kg up to a maximum of 510 mg. All otheraspects of administration will be consistent with the latest ferumoxytolprescribing information. A detailed FMX-MRI protocol will be included inthe study imaging manual. Briefly, each patient will be required tocomplete their FMX-MRIs on the same scanner to reduce inter-scanvariability. Each MRI study will be evaluated for image quality andsignal characteristics of tumors and reference tissue on T1-, T2- andT2*-weighted sequences. Once a completed set of images from each patienthas been received, the images will be loaded onto the viewingworkstation for qualitative review and then sent to a quantitative lab(handled by central imaging CRO) for analysis.

Multiple MR images will be collected on Day 1-Day 2 of the FMX period atvarious time points: a baseline image acquired prior to the FMXinfusion, a second image occurring 1-4 h after the end of FMXadministration, and a third image at approximately 24 h post-FMX, usingthe same protocol and sequences as on Day 1. The body areas to bescanned will be determined by the location of the patient's disease;detailed instructions will be described in the study imaging manual.

Example 8 Clinical Use of Liposomal Irinotecan in Combination with5-Fluorouracil and Leucovorin

Clinical efficacy of MM-398 has also been demonstrated ingemcitabine-refractory metastatic pancreatic cancer patients: in arandomized, Phase 3, international study (NAPOLI-1), MM-398 was given incombination with 5-fluorouracil/leucovorin (5-FU/LV) and significantlyprolonged overall survival (OS) compared to 5-FU/LV treatment alone. Themedian OS for the MM-398-containing arm was 6.1 months compared to 4.2months for the control arm (HR=0.67, p=0.0122). Because the activepharmaceutical ingredient in MM-398 is irinotecan, the safety profilewas as anticipated, qualitatively similar to irinotecan, where the mostcommon adverse events (≥30%) are nausea, vomiting, abdominal pain,diarrhea, constipation, anorexia, neutropenia, leukopenia (includinglymphocytopenia), anemia, asthenia, fever, body weight decreasing, andalopecia (irinotecan package insert). Table 14 provides a summary ofGrade 3 or higher safety data of patients treated with MM-398 plus5-FU/LV from the NAPOLI-1 study. Table 13 provides toxicities observedin the Phase I monotherapy study, for comparison.

TABLE 13 Summary of the most common (>10%) grade 3 or greater adverseevents from the 13 patients treated with MM-398 monotherapy at a dose of80 mg/m² every 2 weeks during the phase I study. Adverse Events ≥ Grade3 in Study MM-398-01-01-02 n (%) Diarrhea 4 (30.8) Hypokalemia 3 (23.1)Abdominal pain 2 (15.4) Anemia 2 (15.4) Nausea 2 (15.4) Neutropenia 2(15.4)

TABLE 14 Summary of Grade 3 or higher AEs from the NAPOLI-1 phase IIIstudy. MM-398 + 5-FU/LV¹ 5-FU/LV² (N = 117) (N = 134) % % GRADE ≥3NON-HEMATOLOGIC AEs IN >5% PATIENTS, %³ Fatigue 14 4 Diarrhea 13 3Vomiting 11 3 Nausea 8 3 Asthenia 8 7 Abdominal pain 7 6 Decreasedappetite 4 2 Hypokalemia 3 2 Hypernatremia 3 2 GRADE ≥3 HEMATOLOGIC AESBASED ON LABORATORY VALUES, %^(3, 4) Neutrophil count decreased 20 2Hemoglobin decreased 6 5 Platelet Count decreased 2 0 ¹Dose: 80 mg/m²MM-398 + 2400 mg/m² over 46 h/400 mg/m² 5- FU/LV q2w ²Dose: 2000 mg/m²over 24 h/200 mg/m² 5-FU/LV weekly × 4, q6w ³Per CTCAE Version 4⁴Includes only patients who had at least one post-baseline assessment

Example 9 Cell Survival for Various TNBC Cell Lines Following SN-38 andPARP Inhibitor Combination Treatment

Tables 15a, 15b, 16a, and 16b provide the results of in vitromeasurements of cell survival for various triple negative breast cancer(TNBC) cancer cell lines to determine the cell viability followingtreatment with SN-38 and/or a PARP inhibitor. Tables 15a and 15b provideIC50 data, and Tables 16a and 16b provide Maximum Kill data.

TABLE 15a IC50 log10 (μM) Cell Line Exp. 1 Treatment BT20 SUM159PT HCC38SN38 −0.18 −2.35 −2.80 Niraparib 2.14 0.35 1.23 SN38 & Niraparib (3ug/ml) −0.67 −3.99 −0.12 SN38 & Niraparib (1 ug/ml) −0.70 −3.42 −4.09SN38 & Niraparib (0.3 ug/ −0.71 −2.85 −4.23 ml) SN38 & Niraparib (0.1ug/ −0.61 −2.87 −4.05 ml) Cell Line Exp. 2 Treatment BT20 SUM149PTSUM159PT SN38 −0.69 0.24 −2.39 Olaparib 1.24 2.40 0.18 SN38 & Olaparib(3 ug/ml) −1.48 −0.19 −3.70 SN38 & Olaparib (1 ug/ml) −1.49 −0.34 −3.31SN38 & Olaparib (0.3 ug/ −1.44 −0.18 −2.92 ml) SN38 & Olaparib (0.1 ug/−1.29 −0.11 −2.92 ml) Cell Line Exp. 3 Treatment BT20 SUM149PT SUM159PTSN38 −0.37 0.27 −2.66 Rucaparib 1.27 1.68 −0.07 SN38 & Rucaparib (3ug/ml) −1.33 −0.16 −3.64 SN38 & Rucaparib (1 ug/ml) −1.47 −0.23 −3.28SN38 & Racaparib (0.3 ug/ −1.48 −0.49 −3.23 ml) SN38 & Racaparib (0.1ug/ −1.24 −0.10 −3.11 ml) Cell Line Exp. 4 Treatment BT20 SUM159PT HCC38SN38 −0.24 −2.33 −2.75 Talazoparib 1.45 −1.03 −1.23 SN38 & Talazoparib(3 ug/ −1.88 −4.01 −3.41 ml) SN38 & Talazoparib (1 ug/ −1.70 −4.01 −4.01ml) SN38 & Talazoparib (0.3 ug/ −1.10 −4.01 −5.46 ml) SN38 & Talazoparib(0.1 ug/ −1.36 −4.01 −2.87 ml)

TABLE 15b IC50 log10 (μM) Cell Line Exp. 1 Treatment HCC1187 HCC1806BT549 SN38 −0.68 −2.08 −0.10 Niraparib 2.11 1.27 2.03 SN38 & Niraparib(3 ug/ml) −1.58 −2.80 −0.39 SN38 & Niraparib (1 ug/ml) −1.45 −2.62 −0.64SN38 & Niraparib (0.3 ug/ml) −1.61 −2.55 −0.74 SN38 & Niraparib (0.1ug/ml) −1.41 −2.52 −0.55 Cell Line Exp. 2 Treatment HCC70 HCC1187 BT549SN38 −0.07 −0.64 −0.04 Olaparib −4.2 × 10⁷ 2.41 2.04 SN38 & Olaparib (3ug/ml) −0.58 −1.77 −0.55 SN38 & Olaparib (1 ug/ml) −0.49 −1.67 −0.48SN38 & Olaparib (0.3 ug/ml) −0.50 −1.35 −0.35 SN38 & Olaparib (0.1ug/ml) −0.48 −1.56 −0.04 Cell Line Exp. 3 Treatment HCC38 HCC1954 BT549SN38 −2.89 −0.97 −0.05 Rucaparib −0.07 1.60 1.75 SN38 & Rucaparib (3ug/ml) 4.93 −1.22 −0.48 SN38 & Rucaparib (1 ug/ml) −3.88 −1.33 −0.57SN38 & Rucaparib (0.3 ug/ml) −4.01 −1.51 −0.49 SN38 & Rucaparib (0.1ug/ml) −3.29 −1.57 −0.52 Cell Line Exp. 4 Treatment HCC1187 HCC1954SKBR3 SN38 −0.98 −0.65 −1.38 Talazoparib 2.28 3.64 −2.8 × 10⁴ SN38 &Talazoparib (3 ug/ml) −1.79 −1.64 −2.05 SN38 & Talazoparib (1 ug/ml)−1.79 −1.51 −2.65 SN38 & Talazoparib (0.3 ug/ −1.94 −1.45 −2.23 ml) SN38& Talazoparib (0.1 ug/ −1.92 −1.29 −2.41 ml)

TABLE 16a Maximum Kill Percent Cell Line Exp. 1 Treatment BT20 SUM159PTHCC38 SN38 100 97 96 Niraparib 100 97 100 SN38 & Nirapatib (3 ug/ml) 100100 SN38 & Niraparib (1 ug/ml) 100 100 93 SN38 & Niraparib (0.3 ug/ml)100 99 100 SN38 & Niraparib (0.1 ug/ml) 100 100 100 Cell Line Exp. 2Treatment BT20 SUM149PT SUM159PT SN38 100 96 97 Olaparib 98 100 94 SN38& Olaparib (3 ug/ml) 98 97 100 SN38 & Olaparib (1 ug/ml) 99 96 97 SN38 &Olaparib (0.3 ug/ml) 100 98 99 SN38 & Olaparib (0.1 ug/ml) 100 96 99Cell Line Exp. 3 Treatment BT20 SUM149PT SUM159PT SN38 100 95 99Rucaparib 100 99 97 SN38 & Rucaparib (3 ug/ml) 92 97 99 SN38 & Rucaparib(1 ug/ml) 100 97 99 SN38 & Rucaparib (0.3 ug/ml) 94 95 100 SN38 &Rucaparib (0.1 ug/ml) 96 100 97 Cell Line Exp. 4 Treatment BT20 SUM159PTHCC38 SN38 100 96 92 Talazoparib 100 94 92 SN38 & Talazoparib (3 ug/ml)100 SN38 & Talazoparib (1 ug/ml) 90 SN38 & Talazoparib (0.3 ug/ 93 ml)SN38 & Talazoparib (0.1 ug/ 93 ml)

TABLE 16b Maximum Kill Percent Cell Line Exp. 1 Treatment HCC1187HCC1806 BT549 SN38 90 93 95 Niraparib 98 100 100 SN38 & Niraparib (3ug/ml) 89 91 94 SN38 & Niraparib (1 ug/ml) 93 92 92 SN38 & Niraparib(0.3 ug/ml) 89 92 92 SN38 & Niraparib (0.1 ug/ml) 89 93 94 Cell LineExp. 2 Treatment HCC70 HCC1187 BT549 SN38 97 100 93 Olaparib 50 87 100SN38 & Olaparib (3 ug/ml) 98 100 SN38 & Olaparib (1 ug/ml) 100 91 96SN38 & Olaparib (0.3 ug/ml) 100 99 94 SN38 & Olaparib (0.1 ug/ml) 100 9996 Cell Line Exp. 3 Treatment HCC38 HCC1954 BT549 SN38 92 94 94Rucaparib 87 100 100 SN38 & Rucaparib (3 ug/ml) 96 93 SN38 & Rucaparib(1 ug/ml) 98 94 92 SN38 & Rucaparib (0.3 ug/ml) 98 95 93 SN38 &Rucaparib (0.1 ug/ml) 97 93 94 Cell Line Exp. 4 Treatment HCC1187HCC1954 SKBR3 SN38 88 100 88 Talazoparib 100 SN38 & Talazoparib (3ug/ml) 89 93 90 SN38 & Talazoparib (1 ug/ml) 89 94 89 SN38 & Talazoparib(0.3 ug/ml) 89 94 100 SN38 & Talazoparib (0.1 ug/ml) 100 96 87

The experiments that generated these data were performed in 384 wellformat. Cells were plated at 1000 cells/well and then incubated for 24hours. Then SN-38 and/or one of four different PARP inhibitors(talazoparib niraparib, olaparib or rucaparib) was added and intubatedfor an additional 24 hours then the wells were washed with PBS to removethe drug and fresh media was added back into the wells. The plates werethen allowed to incubate for 72 hours period. After the 72 hourincubation period the media was removed and cell viability wasdetermined using the CellTiter-Glo® cell viability assay (Promega,Madison Wis.) according to the product instructions. FIGS. 3A and 3B areline graphs that depict cell viability in BT20 and HCC38 breast cancercell lines, respectively, following treatment with SN-38 and/ortalazoparib.

While the invention has been described in connection with specificembodiments thereof, it will be understood that it is capable of furthermodifications and this application is intended to cover any variations,uses, or adaptations of the invention following, in general, theprinciples of the invention and including such departures from thepresent disclosure that come within known or customary practice withinthe art to which the invention pertains and may be applied to theessential features set forth herein. The disclosure of each and everyU.S., international or other patent or patent application or publicationreferred to herein is hereby incorporated herein by reference in itsentirety.

1.-20. (canceled)
 21. A method of treating a patient having a solidtumor, the method comprising i) administering to the patient liposomalirinotecan once every two weeks; and ii) administering aPoly(ADP-ribose) Polymerase (PARP) inhibitor daily for 3 to 10 daysbetween consecutive administrations of the liposomal irinotecan whereinthe PARP inhibitor starting at least 2 days after the liposomalirinotecan and ending at least 1 day prior to the administration ofadditional liposomal irinotecan.
 22. The method according to claim 21,wherein each administration of liposomal irinotecan is administered as adose of 70 mg/m² (free base).
 23. The method of claim 22, wherein thepatient has been diagnosed with a cancer selected from the groupconsisting of: cervical cancer, ovarian cancer, triple negative breastcancer (TNBC), non-small cell lung cancer (NSCLC), small cell lungcancer (SCLC), gastric cancer and a neuroendocrine cancer.
 24. Themethod of claim 23, wherein the patient does not have a BRCA 1 or aBRCA-2 mutation and wherein the PARP inhibitor is selected from thegroup consisting of niraparib, olaparib, veliparib, rucaparib andtalazoparib.
 25. The method according to claim 22, wherein the PARPinhibitor is administered on each of consecutive days 5 to
 10. 26. Themethod of claim 25, wherein the patient has been diagnosed with a cancerselected from the group consisting of: cervical cancer, ovarian cancer,triple negative breast cancer (TNBC), non-small cell lung cancer(NSCLC), small cell lung cancer (SCLC), gastrointestinal stromal tumors,gastric cancer, pancreatic cancer, colorectal cancer, and aneuroendocrine cancer.
 27. The method of claim 26, wherein the patientdoes not have a BRCA 1 or a BRCA-2 mutation and wherein the PARPinhibitor is selected from the group consisting of niraparib, olaparib,veliparib, rucaparib and talazoparib.
 28. A method of treating a patientwith cancer and having a tumor, the method comprising i) administeringto the patient an effective amount of MM-398 liposomal irinotecan; andii) administering to the patient an effective amount of a PARP inhibitorselected from the group consisting of niraparib, olaparib, veliparib,rucaparib and talazoparib, wherein the PARP inhibitor is administeredafter an effective irinotecan plasma clearing interval.
 29. The methodof claim 28, wherein the effective irinotecan plasma clearing intervalis from about 48 to about 120 hours.
 30. The method of claim 29, whereinthe effective irinotecan plasma clearing interval is 2, 3, 4 or 5 days.31. The method of claim 30, wherein the patient does not have a BRCA 1or a BRCA-2 mutation and wherein the patient has been diagnosed with acancer selected from the group consisting of: cervical cancer, ovariancancer, triple negative breast cancer (TNBC), non-small cell lung cancer(NSCLC), small cell lung cancer (SCLC), gastrointestinal stromal tumors,gastric cancer, pancreatic cancer, colorectal cancer, and aneuroendocrine cancer.
 32. The method of claim 31, wherein the effectiveamount of MM-398 liposomal irinotecan is 70 mg/m² (free base)administered during a 90 minute infusion.
 33. The method of claim 32,wherein each administration of the PARP inhibitor is administered at adose of from about 20 mg/day to about 800 mg/day.
 34. A method oftreating a patient diagnosed with cancer and having a solid tumor, themethod comprising administering to the patient an antineoplastic therapyin a 28-day treatment cycle, the antineoplastic therapy consisting of:i) intravenously administering to the patient an effective amount of aliposomal irinotecan antineoplastic agent only on days 1 and 15 of thetreatment cycle, the liposomal irinotecan having an irinotecan terminalelimination half-life of about 26.8 hours and a maximal irinotecanplasma concentration of about 38.0 micrograms/ml; and ii) administeringan effective amount of a PARP inhibitor antineoplastic agent to thepatient on days 5-12 and 19-25 or 3-12 and 17-25 of the treatment cycle.35. The method of claim 34, wherein the PARP inhibitor is selected fromthe group consisting of niraparib, olaparib, veliparib, rucaparib andtalazoparib.
 36. The method of claim 15, wherein the therapeuticallyeffective amount of the liposomal irinotecan is 70 mg/m² (free base)administered during a 90 minute infusion.
 37. The method of claim 16,further comprising administering one or more subsequent 28-day treatmentcycles of the antineoplastic therapy to the patient in the absence ofdisease progression or unacceptable toxicity during the prior treatmentcycle of the antineoplastic therapy.
 38. The method of claim 17, whereinthe patient has been diagnosed with a cancer selected from the groupconsisting of: cervical cancer, ovarian cancer, triple negative breastcancer (TNBC), non-small cell lung cancer (NSCLC), small cell lungcancer (SCLC), gastrointestinal stromal tumors, gastric cancer,pancreatic cancer, colorectal cancer, and a neuroendocrine cancer. 39.The method of claim 18, wherein the patient does not have a BRCA 1 or aBRCA-2 mutation.
 40. The method of claim 19, wherein each administrationof the PARP inhibitor is administered at a dose of from about 20 mg/dayto about 800 mg/day.